Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1969 2
1971 1
1974 1
1975 6
1976 4
1977 2
1978 3
1979 3
1980 10
1981 3
1982 11
1983 13
1984 14
1985 8
1986 13
1987 8
1988 13
1989 14
1990 10
1991 15
1992 16
1993 12
1994 10
1995 18
1996 14
1997 22
1998 22
1999 25
2000 11
2001 27
2002 40
2003 37
2004 34
2005 30
2006 49
2007 45
2008 49
2009 60
2010 68
2011 55
2012 67
2013 53
2014 68
2015 73
2016 100
2017 95
2018 109
2019 130
2020 135
2021 166
2022 160
2023 142
2024 199
2025 235

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,313 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for pi cf
Search for Pio CF instead (1 results)
Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient.
Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS, Benseler SM, Frankovich J, Gorman MP, Van Haren K, Dalmau J, Dale RC. Cellucci T, et al. Neurol Neuroimmunol Neuroinflamm. 2020 Jan 17;7(2):e663. doi: 10.1212/NXI.0000000000000663. Print 2020 Mar. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 31953309 Free PMC article.
New knowledge on anti-IgLON5 disease.
Gaig C, Sabater L. Gaig C, et al. Curr Opin Neurol. 2024 Jun 1;37(3):316-321. doi: 10.1097/WCO.0000000000001271. Epub 2024 Apr 1. Curr Opin Neurol. 2024. PMID: 38563128 Free PMC article. Review.
Second, low levels of neurofilament light chain in serum and cerebrospinal fluid of patients at disease onset could be a predictor of immunotherapy response. ...
Second, low levels of neurofilament light chain in serum and cerebrospinal fluid of patients at disease onset could be a predi …
Clinical manifestations of the anti-IgLON5 disease.
Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, Giordana C, Heidbreder A, Kotschet K, Lewerenz J, Macher S, Martí MJ, Montojo T, Pérez-Pérez J, Puertas I, Seitz C, Simabukuro M, Téllez N, Wandinger KP, Iranzo A, Ercilla G, Sabater L, Santamaría J, Dalmau J. Gaig C, et al. Neurology. 2017 May 2;88(18):1736-1743. doi: 10.1212/WNL.0000000000003887. Epub 2017 Apr 5. Neurology. 2017. PMID: 28381508 Free PMC article.
Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.
Jansen IE, van der Lee SJ, Gomez-Fonseca D, de Rojas I, Dalmasso MC, Grenier-Boley B, Zettergren A, Mishra A, Ali M, Andrade V, Bellenguez C, Kleineidam L, Küçükali F, Sung YJ, Tesí N, Vromen EM, Wightman DP, Alcolea D, Alegret M, Alvarez I, Amouyel P, Athanasiu L, Bahrami S, Bailly H, Belbin O, Bergh S, Bertram L, Biessels GJ, Blennow K, Blesa R, Boada M, Boland A, Buerger K, Carracedo Á, Cervera-Carles L, Chene G, Claassen JAHR, Debette S, Deleuze JF, de Deyn PP, Diehl-Schmid J, Djurovic S, Dols-Icardo O, Dufouil C, Duron E, Düzel E; EADB consortium; Fladby T, Fortea J, Frölich L, García-González P, Garcia-Martinez M, Giegling I, Goldhardt O, Gobom J, Grimmer T, Haapasalo A, Hampel H, Hanon O, Hausner L, Heilmann-Heimbach S, Helisalmi S, Heneka MT, Hernández I, Herukka SK, Holstege H, Jarholm J, Kern S, Knapskog AB, Koivisto AM, Kornhuber J, Kuulasmaa T, Lage C, Laske C, Leinonen V, Lewczuk P, Lleó A, de Munain AL, Lopez-Garcia S, Maier W, Marquié M, Mol MO, Montrreal L, Moreno F, Moreno-Grau S, Nicolas G, Nöthen MM, Orellana A, Pålhaugen L, Papma JM, Pasquier F, Perneczky R, Peters O, Pijnenburg YAL, Popp J, Posthuma D, Pozueta A, Priller J, Puerta R, Quintela I, Ramakers I, Ro… See abstract for full author list ➔ Jansen IE, et al. Acta Neuropathol. 2022 Nov;144(5):821-842. doi: 10.1007/s00401-022-02454-z. Epub 2022 Sep 6. Acta Neuropathol. 2022. PMID: 36066633 Free PMC article.
Amyloid-beta 42 (Abeta42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. ...
Amyloid-beta 42 (Abeta42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the patho …
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Mummery CJ, Börjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, Jonsson M, Schneider A, Rinne JO, Ludolph AC, Bodenschatz R, Kordasiewicz H, Swayze EE, Fitzsimmons B, Mignon L, Moore KM, Yun C, Baumann T, Li D, Norris DA, Crean R, Graham DL, Huang E, Ratti E, Bennett CF, Junge C, Lane RM. Mummery CJ, et al. Nat Med. 2023 Jun;29(6):1437-1447. doi: 10.1038/s41591-023-02326-3. Epub 2023 Apr 24. Nat Med. 2023. PMID: 37095250 Free PMC article. Clinical Trial.
The secondary endpoint was MAPT(Rx) pharmacokinetics in cerebrospinal fluid (CSF). The prespecified key exploratory outcome was CSF total-tau protein concentration. ...
The secondary endpoint was MAPT(Rx) pharmacokinetics in cerebrospinal fluid (CSF). The prespecified key exploratory outcome wa …
Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis.
Guasp M, Giné-Servén E, Maudes E, Rosa-Justicia M, Martínez-Hernández E, Boix-Quintana E, Bioque M, Casado V, Módena-Ouarzi Y, Guanyabens N, Muriana D, Sugranyes G, Pacchiarotti I, Davi-Loscos E, Torres-Rivas C, Ríos J, Sabater L, Saiz A, Graus F, Castro-Fornieles J, Parellada E, Dalmau J. Guasp M, et al. Neurology. 2021 Jul 6;97(1):e61-e75. doi: 10.1212/WNL.0000000000012191. Epub 2021 May 12. Neurology. 2021. PMID: 33980703
Depressive Symptoms and Amyloid Pathology.
Wiels WA, Oomens JE, Engelborghs S, Baeken C, von Arnim CAF, Boada M, Didic M, Dubois B, Fladby T, van der Flier WM, Frisoni GB, Fröhlich L, Gill KD, Grimmer T, Hildebrandt H, Hort J, Itoh Y, Iwatsubo T, Klimkowicz-Mrowiec A, Lee DY, Lleó A, Martinez-Lage P, de Mendonça A, Meyer PT, Kapaki EN, Parchi P, Pardini M, Parnetti L, Popp J, Rami L, Reiman EM, Rinne JO, Rodrigue KM, Sánchez-Juan P, Santana I, Sarazin M, Scarmeas N, Skoog I, Snyder PJ, Sperling RA, Villeneuve S, Wallin A, Wiltfang J, Zetterberg H, Ossenkoppele R, Verhey FRJ, Vos SJB, Visser PJ, Jansen WJ; Amyloid Biomarker Study group; Alzheimer’s Disease Neuroimaging Initiative (ADNI), the A4 Study group, Dominantly Inherited Alzheimer Network (DIAN), European Prevention of Alzheimer’s Dementia (EPAD) consortium, Fundació ACE Healthy Brain Initiative (FACEHBI), Harvard Aging Brain Stud; Alcolea D, Altomare D, Baiardi S, Baldeiras I, Bateman RJ, Blennow K, Bottlaender M, den Braber A, van Buchem MA, Byun MS, Cerman J, Chen K, Chipi E, Day GS, Drzezga A, Eckerström M, Ekblad LL, Epelbaum S, Förster S, Fortea J, Freund-Levi Y, Frings L, Guedj E, Hausner L, Hellwig S, Huey ED, Jiménez-Bonilla JF, Johnson KA, Juaristi AI, Kand… See abstract for full author list ➔ Wiels WA, et al. JAMA Psychiatry. 2025 Mar 1;82(3):296-310. doi: 10.1001/jamapsychiatry.2024.4305. JAMA Psychiatry. 2025. PMID: 39841452
MAIN OUTCOMES AND MEASURES: Amyloid-beta1-42 levels in cerebrospinal fluid or amyloid positron emission tomography scans were used to determine presence or absence of amyloid pathology. ...
MAIN OUTCOMES AND MEASURES: Amyloid-beta1-42 levels in cerebrospinal fluid or amyloid positron emission tomography scans were …
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network–Trials Unit. Salloway S, et al. Nat Med. 2021 Jul;27(7):1187-1196. doi: 10.1038/s41591-021-01369-8. Epub 2021 Jun 21. Nat Med. 2021. PMID: 34155411 Free PMC article. Clinical Trial.
The primary outcome was a cognitive end point; secondary outcomes included clinical, cognitive, imaging and fluid biomarker measures. Fifty-two participants carrying a mutation were assigned to receive gantenerumab, 52 solanezumab and 40 placebo. ...Gantenerumab significan …
The primary outcome was a cognitive end point; secondary outcomes included clinical, cognitive, imaging and fluid biomarker measures. …
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ; Amyloid Biomarker Study Group; Aarsland D, Alcolea D, Altomare D, von Arnim C, Baiardi S, Baldeiras I, Barthel H, Bateman RJ, Van Berckel B, Binette AP, Blennow K, Boada M, Boecker H, Bottlaender M, den Braber A, Brooks DJ, Van Buchem MA, Camus V, Carill JM, Cerman J, Chen K, Chételat G, Chipi E, Cohen AD, Daniels A, Delarue M, Didic M, Drzezga A, Dubois B, Eckerström M, Ekblad LL, Engelborghs S, Epelbaum S, Fagan AM, Fan Y, Fladby T, Fleisher AS, Van der Flier WM, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Frings L, Frisoni GB, Fröhlich L, Gabryelewicz T, Gertz HJ, Gill KD, Gkatzima O, Gómez-Tortosa E, Grimmer T, Guedj E, Habeck CG, Hampel H, Handels R, Hansson O, Hausner L, Hellwig S, Heneka MT, Herukka SK, Hildebrandt H, Hodges J, Hort J, Huang CC, Iriondo AJ, Itoh Y, Ivanoiu A, Jagust WJ, Jessen F, Johannsen P, Johnson KA, Kandimalla R, Kapaki EN, Kern S, Kilander L, Klimkowicz-Mrowiec A, Klunk WE, Koglin N, Kornhuber J, Kramberger MG, Kuo HC, Van Laere K, Landau SM, Landeau B, Lee DY, de Leon M, Leyton CE, Lin KJ, Lleó A, Löwenmark M, Madsen K, Maier W, Marcusson J, Marquié M, Martinez-Lage P, Masere… See abstract for full author list ➔ Jansen WJ, et al. JAMA Neurol. 2022 Mar 1;79(3):228-243. doi: 10.1001/jamaneurol.2021.5216. JAMA Neurol. 2022. PMID: 35099509 Free PMC article.
IMPORTANCE: One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of amyloid pathol …
IMPORTANCE: One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by b …
2,313 results